Clinton Names New NCI Director

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 8
Volume 4
Issue 8

WASHINGTON--President Clinton has appointed Dr. Richard D. Klausner as director of the National Cancer Institute. Dr. Klausner has served as chief, Cell Biology and Metabolism Branch, National Institute of Child Health and Human Development, since 1984. He earned his undergraduate degree at Yale and his MD from Duke.

WASHINGTON--President Clinton has appointed Dr. Richard D. Klausneras director of the National Cancer Institute. Dr. Klausner hasserved as chief, Cell Biology and Metabolism Branch, NationalInstitute of Child Health and Human Development, since 1984. Heearned his undergraduate degree at Yale and his MD from Duke.

In a statement of congratulations from the American Society ofClinical Oncology, John H. Glick, MD, president, called Dr. Klausnera "distinguished molecular biologist . . . with an impressiverecord of scientific and administrative accomplishments at theNIH."

Dr. Harold E. Varmus, NIH director, said that Dr. Klausner "bringsto this important post an extraordinary record of scientific achievement,admirable personal qualities, and a firm commitment to advancingthe nation's health through vigorous and innovative science. Iam sure that Dr. Klausner will provide the leadership that NIH'slargest and most visible institute needs as it carries forwardthe fight against cancer.

Recent Videos
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
2 experts are featured in this video
2 experts are featured in this video
2 experts are featured in this video
4 KOLs are featured in this series.
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
Related Content